Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)Christopher M. Booth, Elizabeth A. Eisenhauer, Marinus W. Lobbezoo et al.|European Journal of Cancer|2007Cited by 109